Antidote

  • Sector: Healthcare / Tech
  • First Invested: 2015
  • Total Invested: £6M
  • Status: Current

 

Antidote is leading an urgent, collaborative effort to advance medical research, and transform the way people connect to it. As a digital health company focused on accelerating and improving medical research, they are combining proprietary technologies, data, and well-established business models to transform the way patients and researchers connect, so that breakthroughs happen faster.

Why is this important? There’s a major problem in medical research today. 85% of patients don’t know about clinical trials, and if they do, it’s incredibly difficult for them to find ones they qualify for. The lack of patient participation leads to 80% of trials being delayed or closed. Medical progress is slowed, and patients continue to wait for answers. That’s why Antidote have taken on the massive job of structuring all clinical trial information and making it machine-readable. This structured data drives Antidote Match, which allows people to find clinical trials that are right for them, just by answering a few questions. It only takes a few clicks to be part of shaping medical history.

To date, Antidote has been widely covered in the press including being featured in the Financial Times, Bloomberg, Forbes, and the Huffington Post. They’ve signed  agreements with many of the biggest players in the pharmaceutical industry, as well as the patient advocacy community.  They’re the first commercial company to partner with the WHO and get access to the International Clinical Trials Registry Platform. And, they were selected to support Joe Biden’s Cancer Moonshot Initiative.

Antidote was launched as TrialReach in 2009 and re-branded to Antidote in 2016. The company is based in the US and the UK. We will be working closely with the team to expand rapidly and accelerate plans to become the industry standard for pharmaceutical companies seeking patients for clinical trials. The additional capital will allow the business to scale up its team and operations domestically, in order to solidify its leadership position.